12:00 AM
 | 
Jan 14, 2013
 |  BC Week In Review  |  Clinical News  |  Regulatory

Omadacycline regulatory update

FDA granted Qualified Infectious Disease Product (QIDP) designation for IV and oral formulations of omadacycline to treat acute bacterial skin and skin structure infections (ABSSSI) and community-acquired bacterial pneumonia (CABP). Paratek plans to begin...

Read the full 150 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >